Please login to the form below

Not currently logged in
Email:
Password:

Afferent Pharma

This page shows the latest Afferent Pharma news and features for those working in and with pharma, biotech and healthcare.

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’s chronic cough drug clears mid-stage trial

MK-7264 reduces coughs per hour by 37%. Merck &Co's purchase of Afferent Pharma last year was all about a candidate drug for chronic cough - so it will be celebrating ... Merck (known as MSD outside North America) stumped up $500m upfront to buy Afferent

Latest news

  • Merck buys cough drug developer Afferent for $1.25bn Merck buys cough drug developer Afferent for $1.25bn

    Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline. ... Merck has been working on its own early-stage R&D programme in the P2X3 area, along with other big pharma

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics